Upstream Bio (NASDAQ:UPB) Releases Earnings Results, Beats Estimates By $0.05 EPS

Upstream Bio (NASDAQ:UPB) issued its quarterly earnings results on Wednesday. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.05, reports. The firm had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.42 million. Upstream Bio had a negative return on equity of 36.48% and a negative net margin of 5,026.03%.

Upstream Bio Trading Up 4.6%

NASDAQ:UPB traded up $0.41 on Wednesday, hitting $9.36. The company’s stock had a trading volume of 815,485 shares, compared to its average volume of 1,064,001. Upstream Bio has a one year low of $7.25 and a one year high of $33.68. The firm has a market capitalization of $509.37 million, a P/E ratio of -3.51 and a beta of 1.28. The stock has a fifty day moving average of $9.17 and a two-hundred day moving average of $19.45.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its holdings in Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after purchasing an additional 2,158 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after purchasing an additional 1,440 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Upstream Bio in the fourth quarter valued at about $45,000. Russell Investments Group Ltd. lifted its stake in shares of Upstream Bio by 1,963.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock worth $57,000 after buying an additional 2,887 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of Upstream Bio during the 1st quarter worth about $115,000.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Evercore cut Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective on the stock. in a research note on Friday, March 27th. Weiss Ratings cut shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded shares of Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.